AU2019365135A1 - Antibody library and method - Google Patents

Antibody library and method Download PDF

Info

Publication number
AU2019365135A1
AU2019365135A1 AU2019365135A AU2019365135A AU2019365135A1 AU 2019365135 A1 AU2019365135 A1 AU 2019365135A1 AU 2019365135 A AU2019365135 A AU 2019365135A AU 2019365135 A AU2019365135 A AU 2019365135A AU 2019365135 A1 AU2019365135 A1 AU 2019365135A1
Authority
AU
Australia
Prior art keywords
antibody
variant
amino acid
dna
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019365135A
Other languages
English (en)
Inventor
Richard Buick
Natasha CAMPBELL
Darragh MACCANN
James MCCLORY
Leona MCGIRR
Hugh Morgan
Anthony O’KANE
Christopher Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fusion Antibodies Ltd
Original Assignee
Fusion Antibodies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1817188.4A external-priority patent/GB201817188D0/en
Priority claimed from GBGB1904754.7A external-priority patent/GB201904754D0/en
Priority claimed from GBGB1905032.7A external-priority patent/GB201905032D0/en
Application filed by Fusion Antibodies Ltd filed Critical Fusion Antibodies Ltd
Publication of AU2019365135A1 publication Critical patent/AU2019365135A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B10/00—Directed molecular evolution of macromolecules, e.g. RNA, DNA or proteins
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2019365135A 2018-10-22 2019-10-22 Antibody library and method Pending AU2019365135A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB1817188.4A GB201817188D0 (en) 2018-10-22 2018-10-22 Antibody library
GB1817188.4 2018-10-22
GB1904754.7 2019-04-04
GBGB1904754.7A GB201904754D0 (en) 2019-04-04 2019-04-04 Antibody library and method
GBGB1905032.7A GB201905032D0 (en) 2019-04-09 2019-04-09 Antibody library and method
GB1905032.7 2019-04-09
PCT/GB2019/053010 WO2020084298A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Publications (1)

Publication Number Publication Date
AU2019365135A1 true AU2019365135A1 (en) 2021-05-13

Family

ID=68393020

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019365135A Pending AU2019365135A1 (en) 2018-10-22 2019-10-22 Antibody library and method

Country Status (10)

Country Link
US (2) US12378696B2 (https=)
EP (1) EP3870607A1 (https=)
JP (2) JP7853096B2 (https=)
KR (1) KR20210084509A (https=)
CN (1) CN113195537A (https=)
AU (1) AU2019365135A1 (https=)
BR (1) BR112021007529A2 (https=)
CA (1) CA3115150A1 (https=)
MX (1) MX2021004149A (https=)
WO (1) WO2020084298A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ． ホフマン－ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
CN112289369B (zh) * 2020-12-15 2021-04-02 武汉华美生物工程有限公司 一种基于深度学习的抗体库构建方法及装置
CN114775065B (zh) * 2022-04-22 2026-01-06 武汉华美生物工程有限公司 一种半合成纳米抗体库构建方法和纳米抗体库
CN115171774A (zh) * 2022-05-17 2022-10-11 慧壹科技(上海)有限公司 一种抗体/大分子药物的亲和力改造系统和方法
CN117736329B (zh) * 2023-12-25 2024-11-12 华润生物医药有限公司 抗pd-1抗体及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011801A1 (en) * 1999-05-27 2009-01-07 Government of the United States as represented by the Secretary, Department of Health and Human Services Immunoconjugates having high binding affinity
WO2016188911A1 (en) * 2015-05-22 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the cath-d catalytic activity and its binding to the lrp1 receptor
CN109576292B (zh) * 2018-12-21 2022-11-29 深圳市爱思迪生物科技有限公司 一种抗体文库的构建方法及其应用

Also Published As

Publication number Publication date
WO2020084298A1 (en) 2020-04-30
MX2021004149A (es) 2021-06-15
EP3870607A1 (en) 2021-09-01
CN113195537A (zh) 2021-07-30
US20250382726A1 (en) 2025-12-18
KR20210084509A (ko) 2021-07-07
CA3115150A1 (en) 2020-04-30
BR112021007529A2 (pt) 2021-08-03
US20210388063A1 (en) 2021-12-16
JP2026016427A (ja) 2026-02-03
JP2022512650A (ja) 2022-02-07
JP7853096B2 (ja) 2026-04-28
US12378696B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
US20250382726A1 (en) Antibody Library and Method
Traxlmayr et al. Construction of a stability landscape of the CH3 domain of human IgG1 by combining directed evolution with high throughput sequencing
JP7692404B2 (ja) 多重特異性抗原結合分子を含む組成物における不純物分子の分析方法
Jung et al. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody VH domains
JP6907335B2 (ja) 抗体の選択方法
US20190048069A1 (en) Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2011160429A1 (zh) 抗p185（her2/erbb2）人源化抗体
TWI825544B (zh) 含異二聚體抗體Ｆｃ的蛋白以及其製備方法
US20140221621A1 (en) Single-chain multivalent binding protein compositions and methods
KR20180034500A (ko) 친화성 크로마토그래피에서의 숙주 세포 단백질 감소 방법
JP7560456B2 (ja) タンパク質中の遊離チオールを特定するための方法
Grimm et al. Ribosome display selection of a murine IgG1 fab binding affibody molecule allowing species selective recovery of monoclonal antibodies
JP2013510591A (ja) 繊維状ファージ上でのジスルフィド結合二量体タンパク質の提示
JP2026508171A (ja) 共通軽鎖抗体ライブラリーとその調製方法及び用途
Tonikian et al. Selecting and purifying autonomous human variable heavy (VH) domains
US20130045895A1 (en) Binding domains
US20260092928A1 (en) Methods of analyzing heterodimeric ¿proteins
CN119735680B (zh) 一种抗cd28的单克隆抗体及细胞
CA2794851A1 (en) Generation of antibodies to an epitope of interest
Girard Investigating the Determinants of Antibody Binding Against a Cancer-Related Glycoprotein The Crucial Role of the Heavy Chain CDRs
WO2026059472A1 (en) Bivalent bispecific antibody and method for producing thereof
HK40075206A (en) Analysis method for impurity molecules in composition containing multi specific antigen binding molecules
CN119855835A (zh) 基于共同轻链产生双特异性抗体的方法
CN121079327A (zh) 用于降低抗体粘度的方法和组合物
KR20220087488A (ko) Pd-l1 결합 분자